Dipexium Pharmaceuticals, a late stage biotech developing a novel antibiotic treatment for diabetic foot ulcers, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $30 million by offering 2.3 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Dipexium Pharmaceuticals would command a fully diluted market value of $101 million.
Dipexium Pharmaceuticals, which was founded in 2010, plans to list on the NASDAQ under the symbol DPRX. Dipexium Pharmaceuticals initially filed confidentially on December 23, 2013. Oppenheimer & Co. is the sole bookrunner on the deal.
